FDA IND clearance enables a phase 1b evaluation of SP16 in chemotherapy-induced pain and peripheral neuropathy, with enrollment planned for mid-2026 at the University of Virginia. Proposed mechanisms ...
ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE)-- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”, “Dogwood” or “the Company”), a company that focuses on developing new non-opioid medicines to ...
On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a ...
ATLANTA - Dogwood Therapeutics, Inc. (NASDAQ:DWTX), a clinical-stage biotech company with a market capitalization of $10.55 million, has secured a royalty-free global license for Serpin Pharma’s SP16, ...
All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia “FDA acceptance of our SP16 IND ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 ...
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results